The Latest Advances In Liver Transplantation At The Pittsburgh Transplantation Institute:

Evolution Of FK506, Liver-Intestinal Transplantation, Clinical Xenotransplantation, And The Induction Of Graft Acceptance

IGNAZIO ROBERTO MARINO, M.D., HOWARD R. DOYLE, M.D.
KAREEM ABU-ELMAGD, M.D., CARLO L. SCOTTI-FOGLIENI, M.D.
RAFAEL MAÑEZ, M.D., ANDREAS G. TZAKIS, M.D.
SATORU TODO, M.D., JOHN J. FUNG, M.D., PH.D.
THOMAS E. STARZL, M.D., PH.D.
PITTSBURGH TRANSPLANTATION INSTITUTE, UNIVERSITY OF PITTSBURGH MEDICAL CENTER AND THE VETERANS ADMINISTRATION MEDICAL CENTER, PITTSBURGH, PA

During the past 30 years orthotopic liver transplantation (OLTx) has become a highly successful form of therapy,\textsuperscript{1-7} and as of this writing it is being performed at more than 100 institutions in the U.S., and a similar number in Europe. This is testimony to the great advances achieved in this field since the 1960s and 1970s, when there were essentially only two places actively engaged in liver transplantation.\textsuperscript{3,8}

Essential to its success have been the technical refinements introduced during the last three decades,\textsuperscript{7,9} which have allowed many surgeons around the world to be able to do the procedure safely. Liver transplantation is still considered as one of the most complex operations, and therefore the margin of error is small and attention to technical detail is crucial to a satisfactory outcome. This is magnified in importance since OLTx, unlike kidney, heart, pancreas and intestinal transplantation, lacks a back-up system, such as dialysis, ventricular assist device, insulin or total parenteral nutrition. Thus, the smallest mistake in the surgical management of the patient may prove fatal.
In this chapter we will describe four major clinical advances in the field of liver transplantation, achieved between 1989 and 1994 at the Pittsburgh Transplantation Institute. First was the introduction of the novel immunosuppressive drug FK506, which after extensive in vitro and in vivo studies was approved by the Food and Drug Administration on April 8, 1994, and is now available for clinical use in the U.S. Second, the feasibility of combined liver-intestinal and multivisceral transplantation as a surgical treatment for patients with simultaneous liver and intestinal failure. Third, the definition of the biological basis of clinical liver transplantation, as well as the strategies for future investigations. Fourth, the attempts to induce graft acceptance (donor-specific nonreactivity) by cell augmentation with simultaneous donor bone marrow infusion.

Each of these four advances will be examined and discussed separately herein. Data are presented as the mean ± SD. Survival curves for both patients and grafts were estimated by the Kaplan-Meier method, and the comparison among the different cohorts within each population was done by a generalized Wilcoxon (Breslow) test.

### FOUR YEARS EXPERIENCE WITH FK506 IN LIVER TRANSPLANTATION

FK506 (tacrolimus, Prograf®), the first baseline immunosuppressive drug to be certified by the FDA in 11 years, became available in pharmacies in the United States on June 1, 1994. Following 3 years of preclinical research in Chiba,16 Pittsburgh,17-21 Cambridge,22-24 and elsewhere, the drug was first used clinically in our center in February, 1989, to successfully treat patients who were undergoing intractable rejection of their liver allografts despite maximum cyclosporine-based therapy.25 A few months later, extensive trials were begun with FK506 as the primary immunosuppressant, for recipients of all of the commonly transplanted organs.26,27 We report here our experience in 1,153 consecutive patients who underwent primary liver allografts under FK506 therapy. The biological effects of this agent, its pharmacokinetics, and assay methods are fully described elsewhere.28-32

### PATIENTS AND METHODS

From August 18, 1989, through August 1, 1993, 1,153 consecutive patients underwent primary OLTx at the Pittsburgh Transplantation Institute, and received FK506 as the primary immunosuppressive agent. Of these, 971 (84%) were adults, while 182 (16%) were children. The mean age was 51 ± 12 years (range: 18-76) for adults and 6 ± 6 years (range: 0.2-17.8) for children. Among the adults, 251 (26%) were over 60 years of age. Table 1 lists the indication for OLTx, based upon the final pathological diagnosis of the explanted liver. Retransplantation was required in 138 (12%) patients; 122 had a second transplant, 15 had a third transplant, and one had 4 grafts. The survival analyses were based on follow-up until October, 1993.

There were 612 patients transplanted between February 19, 1990 and December 21, 1991. Seventy-nine patients were part of a randomized trial that was conducted during that period, comparing cyclosporine to FK506, while the remaining 533 patients were excluded from randomization. The criteria for exclusion were: age < 18 or > 60, positive HBsAg, malignancy, multiple organ transplantation, renal failure, active infection, coma, significant heart or lung disease, previous hepatobiliary and/or portal hypertension surgery, unsatisfactory recipient operation, and liver allograft of uncertain quality.33 The differences between the randomized and nonrandomized patients are summarized in Table 2. The initial phase of the study was carried out during our early learning curve, in which the daily induction doses were two or three times greater than those currently recommended.34-36 Our present policy is to give FK506 initially as a con-

---

### Table 1: Indications for primary liver transplantation with FK506 as the primary immunosuppressive agent, at the Pittsburgh Transplantation Institute.

<table>
<thead>
<tr>
<th>Indication</th>
<th>Nonrandomized (n=533)</th>
<th>Randomized (n=79)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>Nonalcoholic cirrhosis</td>
<td>384 (33)</td>
<td>27 (34)</td>
</tr>
<tr>
<td>Alcoholic cirrhosis</td>
<td>210 (18)</td>
<td>28 (35)</td>
</tr>
<tr>
<td>Autoimmune disorders</td>
<td>204 (18)</td>
<td>17 (22)</td>
</tr>
<tr>
<td>-autoimmune hepatitis</td>
<td>38</td>
<td>1 (1)</td>
</tr>
<tr>
<td>-primary biliary cirrhosis</td>
<td>92</td>
<td>2 (3)</td>
</tr>
<tr>
<td>-primary sclerosing cholangitis</td>
<td>74</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Biliary atresia</td>
<td>93 (8)</td>
<td>5</td>
</tr>
<tr>
<td>Genetic disorders</td>
<td>30 (3)</td>
<td>0</td>
</tr>
<tr>
<td>Primary liver cancer</td>
<td>81 (7)</td>
<td>0</td>
</tr>
<tr>
<td>Fulminant Failure</td>
<td>34 (3)</td>
<td>0</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>117 (10)</td>
<td>0</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td><strong>1,153</strong></td>
<td></td>
</tr>
</tbody>
</table>

---

### Table 2: Clinical features of the randomized and non-randomized patients who underwent primary liver transplant between February 19, 1990 and December 21, 1991 under FK506 (Tracolimus, Prograf®).

<table>
<thead>
<tr>
<th>Condition</th>
<th>Randomized (n=79)</th>
<th>Nonrandomized (n=533)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adults</td>
<td>429</td>
<td>0</td>
</tr>
<tr>
<td>Children</td>
<td>104</td>
<td>0</td>
</tr>
<tr>
<td>OLTx II</td>
<td>70</td>
<td>5</td>
</tr>
<tr>
<td>OLTx III</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>Number of Grafts</td>
<td>615</td>
<td>84</td>
</tr>
<tr>
<td>Liver Disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonalcoholic cirrhosis</td>
<td>15 (28)</td>
<td>27 (34)</td>
</tr>
<tr>
<td>Alcoholic cirrhosis</td>
<td>92 (17)</td>
<td>28 (35)</td>
</tr>
<tr>
<td>Autoimmune disorders</td>
<td>78 (15)</td>
<td>17 (22)</td>
</tr>
<tr>
<td>Biliary atresia</td>
<td>59 (11)</td>
<td>2 (3)</td>
</tr>
<tr>
<td>Genetic disorders</td>
<td>14 (3)</td>
<td>1 (1)</td>
</tr>
<tr>
<td>Tumor</td>
<td>55 (10)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Fulminant failure</td>
<td>23 (4)</td>
<td>0 (0)</td>
</tr>
<tr>
<td>Others</td>
<td>61 (12)</td>
<td>4 (5)</td>
</tr>
</tbody>
</table>
inuous intravenous infusion over 24 hours, at a dose of 0.05 mg/kg. The conversion from intravenous to oral therapy is usually made without any overlap, with a starting oral dose of 0.1 to 0.15 mg/kg twice a day. Dose adjustments were made in the presence of rejection, adverse drug reactions (with special emphasis on nephrotoxicity and neurotoxicity), infection, and according to the functional status of the graft, and always with close attention to the plasma trough levels.

One gram of methylprednisolone was invariably administered intravenously immediately after graft reperfusion. Patients were then placed on 20 mg of prednisone daily and, in the absence of rejection, the dose was gradually reduced over several weeks. Quite frequently, the prednisone was eventually stopped altogether. The first 58 patients, and those who had a strong positive cytotoxic crossmatch, were given a 5-day methylprednisolone taper, starting at 200 mg/day on the first postoperative day and reaching 20 mg/day by the sixth postoperative day. Steroid doses were scaled down appropriately in children. Prostaglandin E1 (Prostin®) was added to the immunosuppressive cocktail of some patients during the first postoperative week (37). Also, a low dose of azathioprine (0.5-2 mg/Kg/day) was given to about 10% of the patients at some time during the postoperative period.

If rejection was documented it was treated with an increase in the maintenance dose of FK506, and a one gram bolus of either methylprednisolone or hydrocortisone. A steroid recycle and/or, more rarely, a 5-day course of OKT3 (5-10 mg/day) was given to patients with moderate to severe rejection episodes.

**RESULTS**

With a mean follow-up of 22 ± 15 months (range: 3-49 months), the overall actuarial patient survival rates were 90%, 87%, 83%, and 75% at 3, 6, 12, and 48 months, respectively (Figure 1). Out of the 1,153 OLTx recipients, 233 (20%) died for various reasons, which are listed in Table 3. The total allografts were 1,308 and 155 (13%) were replaced. However, rejection was the cause of failure for only 6 grafts. The overall graft survival was 81%, 78%, 74%, and 65% at 3, 6, 12, and 48 months, respectively (Figure 1).

As expected, the highly selected randomized group had significantly better patient (p=0.006) and graft (p=0.001) survivals than the non-randomized group (Figure 2). The 2-year patient survivals were 91% and 76%, with graft survivals of 88% and 67%, for the randomized and non-randomized groups, respectively. The survival differences reflect the cumulative detrimental effects of the exclusion criteria that were used for randomization. Patients suffering from either parenchymal or cholestatic liver pathology had high long-term survival rates with our

![Graph](image-url)
immunosuppressive protocol based on FK506, as clearly shown in Figure 3. The need for retransplantation was significantly reduced, being only 12%, and the actuarial patient survival after retransplantation was 75% at 3 months and 54% and at 2 years. We attribute the high survival rate (82% at 12 months) in patients undergoing OLTx for fulminant hepatic failure to our current policy of intensive monitoring of intracerebral blood flow and intracranial pressure, with interventions aimed at maintaining intracranial pressure within normal limits, in addition to the therapeutic advantage offered by FK506 treatment.49 Patients with a primary liver tumor had the lowest long-term survival, 72% at one year and 59% at 2 years, similar to that reported in both the cyclosporine era and the beginning of the FK506 era.41 The most common cause of death was recurrence of the primary tumor, despite the use of adjuvant chemotherapy.

We reported elsewhere the details regarding the incidence and treatment of rejection episodes in primary OLTx patients under FK506 immunosuppression.42 However, it should be emphasized that the lower incidence of rejection with FK506 was in the face of overall lowered corticosteroid use (nearly half of the OLTx patients were steroid free by the third post-transplant month). Other aspects of the Pittsburgh experience with the use of FK506 as a primary immunosuppressant, like drug toxicity, development of opportunistic infections, and drug interactions, as well as other clinical observations, are published elsewhere.43-51

THREE YEARS EXPERIENCE WITH COMBINED LIVER-INTESTINAL AND MULTIVISCERAL TRANSPLANTATION

The first experimental intestinal and multivisceral transplantations were performed over three decades ago. However, for 30 years the intestine was considered to be a "forbidden organ" because of the high incidence of graft loss, either due to technical, immunological, or infectious complications.55-57 The demonstration, in clinical liver transplantation, of the great efficacy of FK506, and the definition of its role in experimental multivisceral transplantation,58,59 justified, in 1990, a renewed interest in clinical liver-intestinal and multivisceral transplantation.60,61

PATIENTS AND METHODS

Our report is based on our experience with the first consecutive series of patients that underwent transplantation of a combined, in continuity, liver-intestinal bloc (21 patients), or of a multivisceral cluster of abdominal organs (8 patients, 2 of whom died during surgery, before the organs could be implanted). The general term "multivisceral transplantation" refers to a class of transplants involving the entire small bowel, transplanted en-bloc with or without one or more segments of the gastrointestinal tract (stomach, duodenum, or colon), and with or without one or more solid upper abdominal organs (liver or pancreas). The multivisceral transplants reported here included liver, pancreas, stomach, duodenum, and small bowel. We will limit most of our discussion to the 27 patients that survived the operation.

There were 11 adults and 16 children, transplanted between July 24, 1990, and April 15, 1993. Most patients had end-stage liver disease, with a mean preoperative serum bilirubin of 19 ± 14 mg/dl. Table IV summarizes the etiologies of the intestinal failure and the indications for combined liver-intestinal or multivisceral transplantations in this group of patients. All donors were ABO identical with the recipients, but HLA matching was totally random and uniformly poor. The lymphocytotoxic crossmatch was positive in 2 of the 21 combined liver-intestinal recipients. No attempts were made to alter the graft's immunogenicity by manipulating its lymphoreticular tissue with anti-lymphocytic immunoglobulins (ALS, ALG, OKT3), or with other immunomodulators (immunosuppressive drugs or irradiation) administered to the donor or to the graft. The details regarding surgical technique have been reported elsewhere.60-67 In the present series, all donors were < 50 years of age (although no age limits have been set for intestinal donors, and we evaluate every donor for possible intestinal donation).61 There were no non-heart beating donors.

The extremely complex management required by this unique group of patients has been reported in detail.54,65 FK506 has been the basic immunosuppressant in this clinical series, along with steroids and prostaglandin E,

Immunosuppressive therapy of ongoing acute cellular rejection of multivisceral grafts includes the same drugs used for induction and maintenance immunosuppression (FK506 and steroids), with the occasional addition of monoclonal anti-

---

**Figure 3:** Kaplan-Meier actuarial patient survival for different liver transplant recipient groups, stratified according to the pathology of the primary liver disease. All patients received FK506 as the primary immunosuppressive agent. (From: Abu-Elmagd K, Bronzert O, Jabbour A, Irish W, Fung J, Ramos H, Marino IR, Dodson F, Selby R, Doyle H, Farnakawa H, Gayowski T, Nour S, Reyes J, Pinna A, Rassouli A, Fontes P, Casavilla A, Jabbour N, Maroun W, Tzakis A, Todo S, Hsibulld S, Starzl TE. Recent advances in hepatic transplantation at the University of Pittsburgh. In: "Clinical Transplants, 1993" Terrasali P.L., ed., 157-152, published by UCLA Theme Typing Laboratory, 1000 Veterans Avenue, Los Angeles, California, 90024. Used by permission).
bodies (OKT3). Drug dosage and route of administration are adjusted according to the severity of the rejection, assessed mainly by a histological grading scale. Intestinal rejection can impair FK506 absorption, with resultant inadequate trough plasma levels. Consequently, optimization of FK506 trough levels, targeting 3-5 ng/ml, should be accomplished by either increasing the baseline enteral dose or by intravenous supplementation. Adequate and prompt immunosuppressive treatment of ongoing acute cellular rejection of multivisceral grafts is usually successful.

RESULTS

Patient Survival

As of June 14, 1994 (18-47 month follow-up), 14 out of the original 29 patients (48.3%) had died. Of the 12 patients that died after surviving the operation, ten had received a combined liver-intestine, while two were multivisceral recipients. The causes of death in the liver-intestine group were either technical complications (n=3), opportunistic infections (n=2), uncontrolled graft rejection (n=2), or disseminated post transplant lymphoproliferative disease (n=3). The two postoperative deaths in the multivisceral group were caused by post transplant lymphoproliferative disease (n=3). The two postoperative deaths in the multivisceral group were diagnosed postmortem, and sepsis with multiorgan failure. Actuarial patient survival was 72.4%, 65.5%, and 58.6% at 6, 12, and 24 months, respectively (Figure 4).

Graft Survival

Figure 5 shows the actuarial graft survival for 29 allografts in 27 patients (2 patients underwent removal of the complete organ block and retransplantation). Graft survival was 70%, 63.3% and 56.7% at 6, 12, and 24 months, respectively. One graft was lost due to lymphoproliferative disease, another was lost to rejection (both were liver-intestine); there were two partial losses: a liver (retransplanted), and a pancreas. All other grafts were lost due to patient death.

Immunological Complications

Rejection. Monitoring of liver-intestine and multivisceral graft rejection is based on clinical, endoscopic, histopathological, radiological, and immunological criteria. Clinical criteria are the keystone for early diagnosis of acute rejection of the intestinal graft. Unlike rejection of other isolated solid organ allografts (e.g., heart, lung, liver, kidney, pancreas), whose diagnosis is mainly made by biopsy and/or functional and laboratory tests, the diagnosis of acute intestinal rejection is primarily based on clinical criteria, which usually present first. Therefore, clinical monitoring and careful examination of the intestinal graft stoma and its output are essential. Due to disruption of the normal intestinal mucosal barrier, bacterial and/or fungal translocation can take place, with subsequent septic complications and/or ARDS-like syndromes.

Routine endoscopic surveillance, together with multiple selective biopsies, are usually performed by terminal ileoscopy, although upper endoscopy is
also sometimes done. They are done twice a week for the first month, once a week for the next two months, monthly for the next three months, and every 3-6 months, or whenever clinically indicated, thereafter.

In the present series, the incidence of intestinal allograft rejection was much higher than that of the liver allografts. In fact, whereas 16 patients did not have any rejection of the liver graft, only 2 (both recipients of combined liver-intestinal grafts) were free of clinical and histopathological signs of intestinal rejection. The mean postoperative time to the first episode was 22 ± 34 days for the combined liver and intestine, and 15 ± 7 days for the multivisceral allografts. On 88 occasions on which both liver and small bowel biopsies were taken simultaneously or closely together, 47 (53%) of the dual specimens had no signs of rejection in either organs, 12 (14%) had rejection in both, 15 (17%) had rejection only in the liver and 14 (16%) had rejection in the intestine only. Chronic rejection was the cause of graft failure in one adult, with a strong positive cytotoxic crossmatch, who received a combined liver-intestine.

**Graft-Versus-Host-Disease (GVHD)** — Monitoring of GVHD is done by clinical examination (fever, skin rash, septic-like syndrome), standard histology, immuno-histochemical techniques (immuno-staining, sex identification after fluorescence-in-situ-hybridization-FISH) and PCR-karyotyping ("DNA fingerprinting"). With these procedures it is possible to differentiate migrating immunocompetent cells from the donor (donor "passenger leukocytes") from recipient cells, as well as to document the immunological injury of the recipient tissues by the infiltrating donor cells. Inadequate immunosuppression is a major risk factor for GVHD. Using standard histology and in situ hybridization techniques, GVHD was unequivocally diagnosed in only one combined liver-intestinal pediatric recipient. Light immunosuppression was attempted early in the postoperative course of this child because of pneumocystis carinii pneumonia and an intestinal anastomotic leak. The skin lesions appeared 10 days after transplantation, and the overall clinical picture simulated life-threatening sepsis. The immunosuppression was reduced significantly, and 13 days later the patient succumbed to multiple organ failure. Therefore, despite of the "historical" fear of high incidence of GVHD documented in experimental intestinal transplantation, our clinical experience has actually shown a minimal occurrence of severe GVHD.

Actually, one of the most intriguing findings from the immunological point of view was the gradual replacement of the donor hematolymphoid cells, in the intestinal wall and mesenteric lymph nodes of the graft, by immunocompetent hematolymphoid cells of the recipient, which rearrange the normal intestinal mucosal immune system architecture. Conversely, donor migratory immunocytes ("passenger leukocytes") originating from the graft migrate at the same time ubiquitously into the recipient blood stream and tissues. This new immunological status ("systemic chimerism") could be the basis of gradual induction of donor specific non-reactivity (tolerance).

**CLINICAL XENOTRANSPLANTATION**

The significant advances achieved in the field of liver transplantation have led to an increased demand for organs, and created a wide replacement between organ availability and supply. As of March 31, 1994, there were 34,493 patients in the United Network for Organ Sharing (UNOS) waiting list, up from 13,115 in December 21, 1987, an increase of 263%. Of these, 3,264 awaited liver transplantation, up from 449 in 1987 (727% increase). The supply of organ donors, on the other hand, underwent a marginal increase between 1988 and 1990 (from 4,085 to 4,514), and has remained relatively stable (4,531 in 1991, 4,521 in 1992, and 4,849 in 1993) thereafter. A wider availability of organs for transplantation would allow an expansion rather than a contraction of the indications for transplantation, and at the same time a relaxation of the patient selection criteria. All these facts clearly justify the renewed interest in xenotransplantation observed in the last decade.

The first three attempts at whole organ xenotransplantation were made in France and Germany between January and April 1906, using a pig, a goat, and a macaque as kidney donors. None of these kidneys functioned because of almost immediate vascular thrombosis, and the human recipients died in less than 3 days. In a further attempt in 1923 by Neuhofer, a lamb was used as a kidney donor, and the patient died 9 days after.

<table>
<thead>
<tr>
<th>Etiology of Intestinal Failure</th>
<th>Intestine + Liver</th>
<th>Multivisceral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gastrochisis</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>Necro. enterocolitis</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Volvulus</td>
<td>3</td>
<td>0</td>
</tr>
<tr>
<td>Intestinal atresia</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Microvillus disease</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Pseudo-obstruction</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

**Adults (n = 11)**

<table>
<thead>
<tr>
<th>Etiology of Intestinal Failure</th>
<th>Intestine + Liver</th>
<th>Multivisceral</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crohn’s disease</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Abdominal trauma</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Celiac A. occlusion</td>
<td>0</td>
<td>3</td>
</tr>
<tr>
<td>S.M.A. thrombosis</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>Desmoid tumor</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>Metastic gastrinoma</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>Budd-Chiari syndrome</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

*These patients had short-gut syndrome due to concomitant superior mesenteric artery (S.M.A.) thrombosis by Protein S deficiency (n=1), Antithrombin III deficiency (n=1) or unknown cause (n=1).

Table 4: Etiology of intestinal failure, and indications for combined liver-intestine and multivisceral transplantations in a group of 21 patients operated at the Pittsburgh Transplantation Institute.
the Hennepin County Hospital, in Minneapolis, transplanted the kidney of a baboon to a 65-year-old woman. The organ functioned for 4 days before its artery clotted.86 A few months later on October 8, 1963, Reemtsma of Tulane University used a Rhesus monkey as kidney donor for a human recipient who survived 12 days. Then, Reemtsma tried again with a series of 6 consecutive chimpanzee kidney grafts.87 One of these xenografts functioned for 270 days.

In December, 1963 and January, 1964, 6 patients received baboon kidneys at the University of Colorado, in Denver.88 All of these kidneys worked immediately and sustained a dialysis-free life for 10 to 60 days. The patients were treated with high doses of azathioprine and prednisone, and 4 of them died of sepsis, while rejection was mainly responsible for the other two deaths. However, the pathology of the rejection was not qualitatively different from that observed in allografts.89 Similar immunopathological events brought to failure, after 20 days, a baboon heart transplanted in 1984 into a 2.2 kg neonate,90 in spite of heavy cyclosporine-steroid immunosuppression. A pig kidney and heart transplanted by Kuss91 and Ross,92 respectively, in the 1960s were hyperacutely rejected in a matter of minutes, demonstrating that the pig was not, and will not be, an easy donor for a human recipient.

The Antiproliferative Drugs — Sir Peter Medawar, in 1969, stated that: "A new solution is therefore called for: the use of heterografts - that is to say, of grafts transplanted from lower animals into man. Of the use of heterografts I can say only this: that in the laboratory we are achieving greater success with grafts between species today than we achieved with grafts within 15 years ago. We shall solve the problem by using heterografts one day if we try hard enough, and maybe in less than 15 years.93 However, the laboratory work performed at different institutions in the following 15-20 years did not bring results that could encourage further clinical trials. In May, 1992 a study performed in Pittsburgh by Murase et al.,94 using a hamster-to-rat xenotransplant model, was discussed at the meeting of the American Society of Transplant Surgeons, in Chicago. Murase's work clearly showed that indefinite survival under FK506 was routinely achievable if it was combined, for the first two post-transplant weeks, with either of two "antiproliferative" drugs that suppress purine (RS 61443) or pyrimidine (brequinar) ribonucleotide synthesis. The use of cyclophosphamide, an alkyating agent with considerable B cell specificity,88,95 allowed similar consistent chronic survival after either heart or liver xenotransplantation. Particularly significant was the fact that a single large dose of cyclophosphamide, given 10 days before the xenotransplant, allowed success in almost 100% of the animals with only daily administration of FK506. This work, together with the previous experience with cyclophosphamide96,97 as an effective drug in clinical transplantation, justified its use in clinical xenograft trials.

The Liver Clinical Xenotransplant Trial — On June 28, 1992, and on January 10, 1993, two patients, age 35 and 62 years, respectively, underwent liver xenotransplantation. Both had end-stage chronic active hepatitis caused by hepatitis B virus (HBV), and were in stage 3 coma during the 24 hours that preceded the surgery. The evidence that the baboon liver is resistant to the HBV,98,99 which reinfec ts most allografts under comparable circumstances,100 prompted the selection of these two candidates, to whom human liver transplantation had already been refused at other institutions. The second patient was far more frail, and underwent splenectomy on the fourth post transplant, while the first had had a splenectomy (for trauma) in 1989. Both patients were immunocompetent at the time of the xenograft, although the first also had an HIV infection.98,99,101-103 These differences may have impacted on the efficacy of the perioperative immune modulation.

The chosen donor animal was the baboon Papio cynocephalus. The technical details of the donor surveillance and selection, as well as of the donor and recipient operations, have been published elsewhere98,99,101-103 and will not be repeated here. The baboon liver reperfused promptly and uniformly in both cases (Figure 6). The post-reperfusion biopsies showed a good liver architecture, with a moderate degree of sinusoidal neutrophilic aggregates. The immunosuppression was based on the use of 4 drugs: cyclophosphamide, FK506, methylprednisolone and PGE1. Doses and routes of administration are shown in Figures 7 and 8. Cyclophosphamide was started 2 days before the xenotransplant, and was given for 56 days (out of 70) in Case 1, and for 10 days (out of 26) in Case 2, with the dose ranging from 0.07 to 10.6 mg/kg/day. FK506 was started on the day of the xenografts and, except for higher doses given during the first 2 postoperative weeks in Case 1, the doses were within standard therapeutic ranges. Detailed

![Figure 6: The baboon liver xenotransplant](https://example.com/figure6.png)
descriptions of the immunosuppressive drug doses and their blood levels have been recently reported elsewhere.\textsuperscript{98,99,101-103} The first patient awoke promptly, was extubated after 17 hours, and was eating and walking 5 days after surgery. He had an almost normal bilirubin for the majority of the 70 days that he survived (Figure 7). He also spent more than 30 days in a regular ward. The second patient, however, remained icteric (Figure 8) and comatose, and was eating and walking 5 days after surgery. He had an almost normal bilirubin, and received frequent albumin infusions. Both patients suffered from hypoalbuminemia, and received frequent albumin infusions.\textsuperscript{98,99,101-103} The first patient went into renal failure on postoperative day 21, while the second patient became anuric immediately after surgery.

Papio cynocephalus normally produces elevated levels of factor VII and low levels of factors IX and XI, as compared to humans. Coagulation profiles were done in both recipients preoperatively and several times postoperatively. Our results, reported elsewhere,\textsuperscript{104} showed that the baboon's coagulation pattern was acquired by the patient after liver xenografting, but this did not affect the clotting ability of the patients.

During their postoperative course, the patients underwent several liver biopsies (6 in patient 1 and 8 in patient 2, including the autopsy specimens). Only the biopsy obtained from the first patient on the 12th postoperative day had signs of mild focal cellular rejection, while no evidence of cellular rejection was detected in any of the other biopsies from either patient.\textsuperscript{98,99,101-103,105} No evidence of HBV reinfection was detectable by immunoperoxidase staining in the liver tissue at any time.

Both baboon livers underwent a dramatic growth after implantation into the larger human recipient, with tripling or quadrupling of the organ volume within the first month.\textsuperscript{102} The cause of death in the first case was diffuse subarachnoid hemorrhage and left uncal brain herniation, secondary to angioinvasive aspergillosis; the second patient died of peritonitis. Details of the necropsies have been reported elsewhere.\textsuperscript{98,99,101-103}

However, cell chimerism was proven in both patients by the presence of baboon DNA in all tissues examined (using PCR amplification of baboon-specific DNA).\textsuperscript{98,99} It should also be noted that, in addition to the liver, the second patient was given a large dose of baboon bone marrow cells (3x108/Kg body weight), after the reperfusion of the baboon liver.

**Analysis of the Two Cases and Strategies for Future Clinical Xenotransplantation.** — The most disquieting fact in our baboon-to-human liver transplant experience was the disparity between the paucity of the histopathologic findings of rejection (which was very encouraging) and the discouraging functional deficiencies of these xenotransplants, which suggested incomplete control of xenograft rejection. The pathology of the transplanted baboon livers was compared to that of 6 baboon kidney xenografts transplanted in Denver in 1963 and 1964.\textsuperscript{85,89} These kidneys, as we mentioned before, functioned for 6 to 60 days. The key pathological finding was an occlusive endothelitis of the graft vessels, presumably antibody-mediated. The pathology of those kidneys removed in 1964 showed distal ischemia, caused by the vascular injury, that appeared to be responsible for the patchy gangrene of the xenografts. In the two recent liver xenotransplants, polymorphonuclear leukocytes were seen in the sinusoids immediately after reperfusion, and biliary sludging was detected at the autopsy. Both the sludging and the appearance of polymorphonuclear leukocytes were compatible with a diagnosis of an aborted hyperacute (humoral) rejection. Complement studies were also consistent with this possibility. Total complement was depleted for most of the critical first 2 weeks, while complement components C3, 4 and 5 became undetectable.

![Figure 7: Clinical course of the first liver xenograft (baboon-to-human) recipient (June 28, 1992). SM Saline-mixed (small-red blood cells); PGE, prostaglandin E; Bx, biopsy; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALP, alkaline phosphatase. (From: Starzl TE, Fung J, Tzakis A, Todo S, Bennett AJ, Mantle IR, Boyles K, Zweifel A, Warty V, Michaels M, Kusne S, Rudert WA, Trucco M. Baboon to human liver transplantation, Lancet 1993; 341:65-71. Used by permission).](image-url)
During this time, circulating immune complexes appeared. After 10 days the complement system was restored, but irreversible damage may have been already done. Although these baboon liver xenografts looked almost normal, closer inspection showed a very fine microsteatosis, which was particularly obvious in the second patient. This may represent a sub-lethal immunological injury that precluded long term success in both cases.

We believe now that these livers were acutely damaged by an incomplete version of a form of rejection that was described, in 1964, in ABO incompatible kidneys, and seen later in kidney allografts transplanted across a positive lymphocytotoxic crossmatch. These were the first descriptions of hyperacute kidney rejection by preformed antigraft antibodies. A few years later, hyperacute kidney rejection was defined in a more sophisticated way as a complement activation syndrome, analogous to the Shwartzman and local Arthus reactions. It was pointed out that, although hyperacute allograft rejection usually was associated with antigraft antibodies, this was not an absolute requirement, a heretical statement at that time. However, the distinction between hyperacute rejection with and without preformed antibodies is merely the difference between the classical pathway of complement activation, in which the first steps are antibody dependent, and the alternative pathway, which does not require an antibody trigger or the participation of complement components C1, C2, and C4. We believe that these hyperacute rejection syndromes, with or without preformed antigraft antibodies, are not fundamentally different from those seen after xenotransplantation of organs between genetically diverse species.

Many methods of manipulating the xenograft recipient have been tried and re-tried since the 1960s, without any definite success. These methods include antibody suppression, antibody depletion, inhibition of the complement cascade, and inhibition of the inflammatory response. Alteration of the xenograft before its implantation, mainly by blocking antibody binding sites with recipient F(ab')2 immunoglobulin fragments, has also been unsuccessful. The introduction of the concept of systemic chimerism, has heightened interest in designing strategies aimed to alter the cell composition of the graft.

The creation of a transgenic pig, to be utilized as a source of organs for clinical xenotransplants, has already started in a few laboratories. The scientists working on this project have embarked on a program to produce pigs transgenic for human regulators of complement activation (e.g. DAF, CD59, and MCP). This is achieved by micro-injection of human genomic DNA fragments into the pronuclei of fertilized porcine oocytes. However, only one of the components of the xenotransplant barrier could be overcome by this strategy (namely, the complement cascade); it is achieved by systemic chimerism, has heightened interest in designing strategies aimed to achieve a complete control of rejection will be achieved by this method alone.

One other extremely fascinating possibility is the production of chimeric organs. Human-to-baboon bone marrow transplantation has already been performed in our laboratories, after conditioning with non-lethal irradiation. In this experiment, two baboons preconditioned with 7.5 Gy total lymphoid irradiation were given 6x10⁸/Kg body weight unaltered human bone marrow cells, without any subsequent treatment. Donor DNA was found widely distributed in the tissues of both animals when they were sacrificed, 18 months later. It is also interesting to note that GVHD did not occur in either animal. As recently stated elsewhere: "it remains to be seen if incomplete or even full chimerism will change the image of baboon organs enough to make them viewed as allografts by humans." In conclusion, the impression we want to leave is that with
a combination of modern immunosuppressive agents and donor cell manipulation the prospect of successfully performing clinical xenografts seems today closer than ever.

**INDUCTION OF GRAFT ACCEPTANCE**

The mechanisms through which allografts are able to weather the initial recipient immune system attack, and later allow for two cell populations (donor and recipient) to coexist with less and less need for immunosuppression, was not well understood until recently. It has been postulated by us that the migration of donor leukocytes from transplanted organs, facilitated by immunosuppressive drugs, and the ubiquitous persistence of these cells in the recipient tissues, are the seminal explanation for the occurrence of microchimerism. Also, this cell migration is the first stage in the development of donor specific nonreactivity, and the necessary pathway to allograft acceptance.

Observations compatible with this concept were already reported more than 30 years ago, when azathioprine and prednisone were introduced as combined immunosuppression for kidney transplantation. In fact, there is a characteristic cycle of kidney allograft rejection, in the first few days or weeks post transplant, that can be reversed with steroids. The ability to reduce and sometimes even to stop the immunosuppression was thereafter confirmed in cases of transplantation of the liver, heart and other solid organs. More recently, study of transplanted abdominal organs and their host have provided unique insights into these processes.

In 1969 it was noted that the Kupffer cells and other tissue leukocytes became predominantly of recipient phenotype within 100 days of transplantation, while the hepatocytes permanently retained their donor specificity. This transformation was long assumed to be unique to the hepatic allograft.

However, 22 years later, first in rat models, and then in humans, it was realized that the same process occurred in all successfully transplanted intestines (see previous section), and other organs, differing quantitatively (and perhaps qualitatively) in the number of substituted tissue leukocytes, being greatest with the liver. In 1992, the fate of the leukocytes vacating the grafts was determined by studying the longest survivors after kidney (30 years) or liver transplantation (23 years). Biopsies were obtained from these patients, and from more recently transplanted patients that received hearts, lungs, or intestines. Samples were taken from the transplanted organ, as well as from the patient’s own skin, lymph nodes, and other tissues. After special staining procedures (immunostaining or sex identification after fluorescence in situ hybridization [FISH]), it was possible to determine if the individual cells had come from the donor organ, the recipient’s own body, or both. In confirmatory investigations, the donor and recipient contributions to any specimen could be separated by polymerase chain reaction (“DNA fingerprinting”) techniques.

From these analyses, supporting laboratory experiments in animals, and the most recent experience with baboon-to-human transplants, it became clear that within minutes after restoring the blood supply of any transplant, myriads of sessile, but potentially migratory leukocytes that are part of the normal structure of all organs (passenger leukocytes) left the allograft or the xenograft and migrated ubiquitously; at the same time they were being replaced in the transplanted organ by similar recipient immunocytes, under the protection of immunosuppressive drugs (urea 9). In this new context, the drugs could be viewed as traffic directors, allowing movement of leukocytes to and from the allograft or the xenograft, but preventing the immune destruction that is the normal purpose of this traffic. Because of this bidirectional cell traffic, an immunological status can be reached in which immunosuppression can be stopped, particularly after liver transplantation. Such a stable immunological condition can be achieved more easily with the liver than with any other graft, because of the high concentration in the liver of those critical leukocytes that apparently include pluripotent stem cells.

**PATIENTS AND METHODS**

In a direct extension of this described leukocyte chimerism that occurs spontaneously with whole organ allo- and xenotransplantation, we augmented the host leukocyte load by perioperative infusion of unmodified donor bone marrow to 36 organ recipients who were treated with a conventional regimen of FK506 and prednisone immunosuppression. We report herein only on the first 18 patients, treated between December 1992 and December 1993, and for whom a follow-up of 4 to 16 months is available. Ten patients received a kidney trans-
plant, 7 received a liver, and 1 received a heart, including 3 diabetics with no detectable serum C-peptide who also received pancreatic islets intraportally. Their mean age was 46 ± 13.2 years, (range 20 to 63). The cadaveric donors were ABO identical with their recipients, and all patients received 3 × 10^8 donor bone marrow cells/Kg of recipient body weight, at the time of the solid organ graft.

RESULTS

All patients are presently well, and have excellent function of their transplanted organs. Persistent multilineage leukocyte chimerism was found in the blood of 17 of these 18 recipients, using either flow cytometry and qualitative or quantitative PCR techniques for detection of donor HLA alleles or, additionally, Y chromosomes in female recipients of male organs. In the only patient in whom chimerism could not be demonstrated, the use of a 5-antigen HLA matched, same-sex donor precluded the use of these markers. Rejection was diagnosed and successfully treated in 9 (50%) of the 18 recipients, and transient GVHD occurred in 2 (11%). Donor specific hyperreactivity at variable times postoperatively was demonstrable in vitro tests in the majority of the recipients, and could be identified as early as 50 days post-transplant. It is now too early to attempt discontinuation of the immunosuppressive therapy, however, the pronounced trend to donor-specific nonreactivity (tolerance) revealed by the in vitro tests is very encouraging.

CONCLUSIONS

During the last 15 years, survival after orthotopic liver transplantation has dramatically improved. This has been due to advanced medical technology, and important technical refinements.\(^5,6\) Better organ preservation,\(^6\) and new potent immunosuppressive drugs.\(^5,147\) The recent introduction of FK506 has further improved the survival and the quality of life of liver transplant recipients, compared with our previous experience.\(^147\) Summary of the worldwide experience with FK506 was presented during the 1991 First International Congress on FK506, and has been published elsewhere.\(^148\) FK506 completed on April 8, 1994, its "fast track" journey through the Food and Drug Administration, and it is now commercially available in the U.S.

The recent achievement of satisfactory long-term survival of patients treated with combined liver-intestinal and multivisceral transplantation justifies a continuation of the clinical trials. However, the surveillance and intensity of care required by these patients for the first year, and in most instances thereafter, was very high, far more than at comparable times after the transplantation of the liver alone. Further immunologic and surgical strategies will be required to increase the practicability and the success of such creative surgery.\(^65\)

Although our recent attempts at baboon-to-human xenotransplantation failed, there were encouraging outcomes. First, the xenografts had no evidence of B virus infection during their post-transplant survival of 70 and 26 days in B virus carriers. Second, there also was little histopathologic evidence of humoral or cellular rejection of both liver xenografts. Nonetheless, the function of both xenografts was unsatisfactory. This could be explained by a damage caused by a complement activation syndrome precipitated by classical pathway or independent of antibodies (alternative pathway). Third, the discovery that chimerism easily occurs after baboon-to-human transplants, and after human-to-baboon bone marrow transplant, can possibly open new avenues for the feasibility of clinical xenotransplantation.

The discovery that immunosuppressive drugs can lead to tolerance induction, by allowing a previously unrecognized common mechanism of cell migration and microchimerism to occur, has important therapeutic and clinical implications.

Because the chimeric leukocytes dispersed from the allograft are of bone marrow origin, a therapeutic corollary was that acceptance of less favored organs such as the heart and kidney (or even the liver itself) could be facilitated by the infusion of unaltered donor bone marrow perioperatively. Donor leukocyte infusion to induce tolerance was the best therapeutic strategy of transplantation immunology, but perhaps the least well understood. It was first used by Main and Prehn\(^149\) who showed that lethally irradiated adult mice reconstituted with allogeneic bone marrow could accept skin from the same donor strain but no other. These were efforts to mimic the two conditions (inoculation of mature donor immunocytes and immunologic non-reactivity of recipients) that had allowedBillingham, Brent and Medawar\(^150\) to induce acquired tolerance of neonatally or perinatally injected mice. Hundreds of similar experiments, as well as the treatment policies in the clinical field of bone marrow transplantation, have assumed the need for either a natural or imposed state of host non-reactivity. The resultant risk of GVHD from liver donor cells, described by Billingham and Brent,\(^151\) has been so great in the presence of MHC incompatibility that their use has been largely avoided.

Armed with the discoveries that natural chimerism from the graft itself begins within minutes of organ revascularization, and is persistent, it was possible during 1993 to simulate this timing in unconditioned patients whose transplanted organ, routine immunosuppression, and adjacent bone marrow all arrived perioperatively. The ambitious goal of these projects is to induce a condition of donor-specific tolerance, both in allo- and xenotransplantation, preserving all the functions of the host immune system. These achievements, along with the demonstration that xenotransplantation and intestinal transplantation are a clinical possibility and not any longer futuristic projects, will be chronicled as some of the most significant advances in medicine. When all these become a reality the work started by Sir Peter Medawar will be completed.\(^51\)

REFERENCES

5. Calne RY, Rolles K, White DJG, Thiru S, Evans DB, Mc Master P, Dunn DC, Craddock GN, Henderson RG, Aziz S, Lewis P: Cyclosporin A initially as the only immuno-


77. Marino IR, Doyle HR, Doria C, Aldighetti L, Fung JJ, Starzl TE: Liver transplantation outcome using donors 60 to 79 years of age. Abstract, accepted at the XVth World Congress of The Transplantation Society, Kyoto, Japan, August 28 - September 2, 1994.


88. Starzl TE, Marchiori TL, Peters GN, Kirkpatrick CH, Wilson WEC, Porter KA,


